數據解讀：用藥組比對照組住院人數減半；用藥組無病死，而對照組病死八人。對許多美國佬而言，不死人的不算病

A planned interim analysis of 775 patients in Merck's study looked at hospitalizations or deaths among people at risk for severe disease. It found that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after treatment. That compared with a hospitalization rate of 14.1% for placebo patients. There were also eight deaths in the placebo group.

摘自LZ貼中鏈接。